BioHarvest Sciences plans to dual-list its ordinary shares on Nasdaq and the Tel Aviv Stock Exchange, with registration covering all 22,667,842 outstanding common shares. The company expects TASE trading to start September 8, 2026, saying the move should broaden access to its shares and deepen ties with Israel’s Investment community.
Key Highlights
- Up to 4,516,021 common shares are available for future issuance under BioHarvest Sciences’ Equity Incentive Plan.
- Investor warrants cover 610,742 additional common shares issuable upon exercise.
- TASE trading is expected to begin on September 8, 2026, under the English symbol BHST.
BIOHARVEST SCIENCES INC. (NASDAQ: BHST) plans to add trading on the Tel Aviv Stock Exchange, with the proposed dual listing covering all 22,667,842 outstanding common shares. TASE trading is expected to begin September 8, 2026.
Equity Plan and Warrants Expand Registration Scope
That pool includes 2,564,876 outstanding Options and 269,521 restricted share units, while 1,681,624 shares remain available for future grants.
TASE Listing Targets Israeli Investor Access
BioHarvest says the additional venue is intended to broaden access to its shares and strengthen its connection with the Israeli investment community. The common shares remain listed on the Nasdaq Capital Market, while the TASE line is expected to use the English symbol BHST and an alternative Hebrew symbol. CEO Dr. Zaki Rakib described the dual-listing plan as a natural step for an Israeli-founded company with global ambitions. He linked it to a new growth phase built on the Botanical Synthesis platform and its commercial opportunities.
FAQs
Q: When will BioHarvest Sciences shares begin trading on TASE?
A: BioHarvest Sciences expects its shares to start trading on the Tel Aviv Stock Exchange on September 8, 2026. The English trading symbol is BHST.
Q: How many BioHarvest shares are covered by the TASE registration?
A: The request covers all 22,667,842 outstanding common shares, plus up to 4,516,021 shares available under the equity incentive plan. It also includes warrant-linked shares.
Q: What is the investor impact of BioHarvest’s dual listing?
A: BioHarvest says the TASE dual listing is intended to broaden access to its shares and strengthen its connection with Israel’s investment community. Any future issuance and listing of additional Common Shares is subject to TASE approval.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.